Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
3Cr Bioscience Ltd. has 1 pending office action active in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit, reflecting a highly specific area of focus for the company's current intellectual property efforts. The limited number of pending matters suggests a streamlined or early-stage prosecution phase.
The busiest examiner for the portfolio is HOPPE, EMMA RUTH, who is responsible for 1 pending office action. Since this accounts for the total 1 pending office action, the company's immediate success in the Biotechnology & Pharmaceuticals field depends on the outcome of this single examination. The involvement of only 1 distinct examiner and 1 distinct art unit simplifies the administrative burden of tracking multiple cases.
Practitioners should focus on the specific requirements of the 1 distinct art unit involved in this case. With HOPPE, EMMA RUTH as the sole examiner for the 1 pending office action, the dialogue is highly personalized. This concentrated prosecution profile allows for a deep focus on the technical merits of the single active application in the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPPE, EMMA RUTH | 1 | 40.0% | +58.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18722768 | METHOD FOR DETECTING TARGET SEQUENCES | HOPPE, EMMA RUTH | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18722768 | METHOD FOR DETECTING TARGET SEQUENCES | HOPPE, EMMA RUTH | 1683 | §103§112DP | Non-Final OA | — | Pending | Jun 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial3Cr Bioscience Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Emma Ruth Hoppe has the most, with 1 of 3Cr Bioscience Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
